Castle Biosciences Reports Second Quarter 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall St set to open higher after inflation data, earnings boost
- Oil prices rise after ship attacks, US-Iran talks deadlock
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Castle Biosciences Inc. (CSTL) Tops Q2 EPS by 31c, Revenues Beat
September 3, 2019 4:09 PM EDTCastle Biosciences Inc. (NASDAQ: CSTL) reported Q2 EPS of ($1.05), $0.31 better than the analyst estimate of ($1.36). Revenue for the quarter came in at $10.7 million versus the consensus estimate of $7.48 million.
Q2 2019 DecisionDx-Melanoma test report volume increased 27% compared to Q2 2018Q2 2019 recognized revenues increased to $10.7 million, up from $4.0 million in Q2 2018Q2 2019 gross margin increased to 81%, up from 67% in Q2 2018We are pleased with our strong second quarter performance, including our 27% year-over-year growth in DecisionDx-Melanoma test report volume, which we believe was largely driven by our successful first quarter 2019 commercial... More
